Zobrazeno 11 - 20
of 31
pro vyhledávání: '"Karin Bowen"'
Autor:
Åsa Hellqvist, Yuying Gao, Alexander Macdonald, Karin Bowen, Yanan Zheng, Ye Guan, Lu Liu, Lubna Abuqayyas, Gene L. Colice
Publikováno v:
Airway pharmacology and treatment.
Autor:
Peter Wessman, Gene L. Colice, Mattis Gottlow, Ilya Lipkovich, Karin Bowen, David Svensson, Monika Huhn
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-17 (2019)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed to ident
Autor:
Jean-Pierre Llanos-Ackert, Mark C. Liu, Jonathan Corren, Karin Bowen, Kinga Sałapa, Gene L. Colice
Publikováno v:
Disease modulation within severe asthma.
Introduction and Objectives In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced annualized asthma exacerbation rates (AAER) by up to 71% versus placebo in adults with severe, uncontrolled asthma. We evaluated the effect of tezepelumab on
Autor:
Teresa Piechowiak, Primal Kaur, Esther Garcia Gil, Gun Almqvist, Tor Skärby, Janet M. Griffiths, Karin Bowen, May Mo, Michael E. Wechsler, Gene L. Colice, Åsa Hellqvist
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS), often at
Autor:
Karin Bowen, Latifa Chachi, Claire Emson, Gene L. Colice, Christopher E. Brightling, Jane R. Parnes, Sarah Diver, Ayman Megally, John Downie, Cherrie Small
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Background Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human monoclonal
Autor:
Sandhia Ponnarambil, Gennaro Ruberto, Primal Kaur, Gun Almqvist, May Mo, Gene L. Colice, Andrew Menzies-Gow, Karin Bowen, Esther Garcia Gil, Åsa Hellqvist, Janet M. Griffiths
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)
Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and sta
Autor:
Gene L. Colice, Andrew Menzies-Gow, Karin Bowen, Åsa Hellqvist, Sandhia Ponnarambil, John Downie
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Background Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid-sparing potential of tezepelumab are being investigated in two ongoin
Autor:
Mark C. Liu, Gene L. Colice, Jonathan Corren, Jean-Pierre Llanos-Ackert, Kinga Sałapa, Karin Bowen
Publikováno v:
Airway pharmacology and treatment.
Background: In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced annualized asthma exacerbation rates (AAER) by up to 71% versus placebo in adults with severe, uncontrolled asthma. We evaluated the effect of tezepelumab on exacerbations i
Autor:
S. Lago, Susan Lovick, Gyula Ostoros, P. Lishkovska, Elaine Kilgour, Wilfried Eberhardt, Andrea Fülöp, Alexander Kohlmann, Gabriella Mariani, Paul D. Smith, Karin Bowen, G. Girotto, Astrid McKeown, David J. Carlile, Pasi A. Jänne, Jean-Charles Soria, Egbert F. Smit, Carlos Dias Maciel, Juergen R. Fischer
Publikováno v:
Annals of Oncology
Background Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated safety and efficacy of sel
Autor:
Jean-Pierre Llanos-Ackert, Jonathan Corren, Gene L. Colice, Kinga Sałapa, Karin Bowen, Gabriel Thabut
Publikováno v:
Revue des Maladies Respiratoires Actualités. 13:82-83
Introduction Le tezepelumab est un anticorps monoclonal humain bloquant l’activite de la lymphopoietine stromale thymique. Dans l’etude de phase IIb PATHWAY ( NCT02054130 ), le tezepelumab a significativement reduit les taux annualises d’exacer